Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium Subcutaneous amivantamab-lazertinib demonstrated noninferior ...
Hosted on MSN
BrightSpring raises 2025 revenue guidance to up to $12.8B while expanding specialty and infusion growth
CEO Jon Rousseau highlighted that "the third quarter exceeded our expectations and our ongoing commitment to high-value and high-quality services, operational execution and continuous improvement" ...
Diabetes Division, Katholisches Klinikum Bochum, St Josef Hospital, Ruhr University Bochum, Bochum, Germany Despite the successful development of new therapies for the treatment of type 2 diabetes, ...
Objective To determine if continuous subcutaneous insulin infusion (CSII) therapy is associated with lower glycated haemoglobin (HbA1c) variability (long-term glycaemic variability; GV) relative to ...
It looks like you're using an old browser. To access all of the content on Yr, we recommend that you update your browser. It looks like JavaScript is disabled in your browser. To access all the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback